Lotus Pharmaceutical Co (TPE:1795) LT-Debt-to-Total-Asset: 0.41 (As of Dec. 2025)

What is Lotus Pharmaceutical Co LT-Debt-to-Total-Asset?

Lotus Pharmaceutical Co TPE:1795 76 LT-Debt-to-Total-Asset is 0.41 as of Dec. 2025. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$451.29 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lotus Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.41.

Lotus Pharmaceutical Co's long-term debt to total assets ratio increased from Dec. 2024 (0.21) to Dec. 2025 (0.41). It may suggest that Lotus Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Lotus Pharmaceutical Co (TPE:1795) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lotus Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Lotus Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lotus Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Lotus Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.29

0.21

0.41

Lotus Pharmaceutical Co Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.21	0.16	0.17	0.41

76GF Score

Lotus Pharmaceutical Co Ltd TPE:1795

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lotus Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Lotus Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	43166.077	/	106153.931
	=	0.41

Lotus Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	43166.077	/	106153.931
	=	0.41

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.41 mean?

Lotus Pharmaceutical Co (TPE:1795) has a LT-Debt-to-Total-Asset of 0.41 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lotus Pharmaceutical Co and its competitors.

Is Lotus Pharmaceutical Co's LT-Debt-to-Total-Asset too high?

Lotus Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.41. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Lotus Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Lotus Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.41 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lotus Pharmaceutical Co and its competitors. Lotus Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lotus Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$451.29, compared to a current price of NT$204.00 — trading 54.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.41. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current LT-Debt-to-Total-Asset is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$204.00 is trading 54.8% below its estimated GF Value™ of NT$451.29. GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for TPE:1795:

LT-Debt-to-Total-Asset: 0.41
GF Value™: NT$451.29 vs. price of NT$204.00 (54.8% below fair value)
GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lotus Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TPE:6472 ROCO:4123 ROCO:4105 TPE:1789 ROCO:4114 ROCO:6620 TPE:3705 TPE:1707 ROCO:6576 TPE:1720 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address Song Ren Road, No. 277, 17th Floor, Xin Yi District, Taipei, TWN, 11046

Website https://www.lotuspharm.com

Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.

76GF Score

Get the complete analysis for TPE:1795

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$204.00

Price

NT$451.29

GF Value

View TPE:1795 Analysis

See LT-Debt-to-Total-Asset data for all stocks →